[BioPhenoMA Co., Ltd.] BioPhenoMA aims to develop dementia biomarkers with major leading manufacturers
BioPhenoMA Co., Ltd. Press release: September 26, 2024 Dear one BioPhenoMA aims to develop dementia biomarkers together with major leading manufacturers BioPhenoMA and a leading manufacturer begin joint research on blood biomarker testing reagents for Alzheimer’s disease
https://prcdn.freetls.fastly.net/release_image/132552/5/132552-5-1d59b7bfbf9a2c90ad55132e3967333f-3543×1062.png
[Summary] BioPhenoMA Co., Ltd. (Shinjuku-ku, Tokyo, CEO: Naoto Fujii, hereinafter referred to as BioPhenoMA) has recently concluded a joint research agreement with a leading manufacturer that has attracted attention to our technology. With the conclusion of this agreement, BioPhenoMA will accelerate its business development utilizing ultra-trace protein quantification technology “TN-cyclon(TM).” ■Research overview With the arrival of an aging society with a declining birthrate, the number of patients with Alzheimer’s disease continues to increase. Although fundamental treatment is still difficult, early detection and therapeutic intervention are making it possible to slow the progression. Alzheimer’s disease is caused by the accumulation and aggregation of specific proteins in the brain, such as amyloid-β and phosphorylated tau. In addition, it has been found that the above proteins pass through the blood-brain barrier and exist in small amounts in peripheral blood. Clinical research results have also been reported showing that it has the same diagnostic ability as the method [1]. BioPhenoMA’s highly sensitive measurement technology “TN-cyclon(TM)” is a patented technology that amplifies signals by combining enzyme-linked immunosorbent assay (ELISA) and enzyme cycling. Since this method does not require any special equipment for detection, it can efficiently promote the development of highly sensitive assays, and will also allow for smooth market expansion to testing centers and on-site locations in the future. This time, BioPhenoMA and a major leading manufacturer, who have highly evaluated the potential of these “TN-cyclon(TM)”, have decided to work together on this theme. BioPhenoMA Co., Ltd.
https://www.biophenoma.com/ A startup (established in April 2023) that has the core technology “TN-cyclon (TM)”, which is capable of detecting and quantifying extremely small amounts of proteins, developed by Waseda University Professor Etsuro Ito and others. We believe that the detection and quantification of ultra-trace amounts of proteins are important for analyzing the mechanisms of biological phenomena. We are promoting research and development with the mission of “contributing to progress.” [1] Sebastian Palmqvist et. al., “Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care”, JAMA online July 28, 2024.
doi:10.1001/jama.2024.13855
